CagriSema---a fixed-dose combination therapy of 2.4mg semaglutide with 2.4mg cagrilintide
According to a Phase II trial of CagriSema (NCT04982575), the combination therapy caused a decrease in bodyweight at Week 32 of treatment by 15.6% from baseline. On the other hand, in the SURMOUNT-1 Phase III trial (NCT04184622), Zepbound caused a bodyweight decrease at 72 weeks of 15% from baseline at the lowest dose, and 20.9% at the highest dose (15mg). These results suggest that CagriSema is likely to cause a bigger change in body weight from baseline than even the highest dose of Zepbound, in a fixed amount of time.
CagriSema
2.4mg semaglutide+2.4mg cagrilintide)*10vials:$170
(5mg semaglutide+5mg cagrilintide)*10vials:$300
We are the only peptide company in China that can supply CagriSema. We also supply semaglutide, tiezepatide, retatrutide and other peptide products and raw materials.
If interested please contact whatsapp: +44 7985 116024
According to a Phase II trial of CagriSema (NCT04982575), the combination therapy caused a decrease in bodyweight at Week 32 of treatment by 15.6% from baseline. On the other hand, in the SURMOUNT-1 Phase III trial (NCT04184622), Zepbound caused a bodyweight decrease at 72 weeks of 15% from baseline at the lowest dose, and 20.9% at the highest dose (15mg). These results suggest that CagriSema is likely to cause a bigger change in body weight from baseline than even the highest dose of Zepbound, in a fixed amount of time.
CagriSema
2.4mg semaglutide+2.4mg cagrilintide)*10vials:$170(5mg semaglutide+5mg cagrilintide)*10vials:$300
We are the only peptide company in China that can supply CagriSema. We also supply semaglutide, tiezepatide, retatrutide and other peptide products and raw materials.
If interested please contact whatsapp: +44 7985 116024
